- Conference call with investment community to follow at 8:30 a.m. EDT -

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) today announced that the Company will report its financial results for the first quarter 2015, on Tuesday, May 12, 2015 prior to a conference call with the investment community, scheduled at 8:30 a.m. EDT.

Investors and the public are invited to access the live audio webcast through the link below. Participants who would like to ask questions during the question and answer session must participate by telephone also. Participants are encouraged to log-in and/or dial-in fifteen minutes before the conference call begins. The webcast replay is expected to be available on our investor website, http://ir.navidea.com, approximately two to four hours after the live event.

      Event: Navidea Biopharmaceuticals Q1 2015 Financial Results Conference Call Date/Time: Tuesday, May 12, 2015 at 8:30 a.m. EDT Webcast Link:

http://edge.media-server.com/m/p/yafuo9zw/lan/en

Dial-in Number – US: 1 (855) 897-5884 Dial in Number – Int’l: 1 (720) 634-2940

Confirmation Number:

39734236

Replay:

A webcast replay will be available on the Investor Relations section of our website at http://ir.navidea.com for 30 days.

 

About NavideaNavidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents. Navidea is developing multiple precision-targeted products and platforms including Manocept™ and NAV4694 to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013 and in Europe in November 2014. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and therapeutics, and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit www.navidea.com.

Navidea BiopharmaceuticalsInvestorsTom Baker, 617-532-0624tbaker@navidea.comorMediaSharon Correia, 978-655-2686Associate Director, Corporate Communications

Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Navidea Biopharmaceuticals Charts.
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Navidea Biopharmaceuticals Charts.